JP2021523712A - 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法 - Google Patents

安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法 Download PDF

Info

Publication number
JP2021523712A
JP2021523712A JP2020563659A JP2020563659A JP2021523712A JP 2021523712 A JP2021523712 A JP 2021523712A JP 2020563659 A JP2020563659 A JP 2020563659A JP 2020563659 A JP2020563659 A JP 2020563659A JP 2021523712 A JP2021523712 A JP 2021523712A
Authority
JP
Japan
Prior art keywords
ser
pro
thr
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020563659A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019217922A5 (https=
JP2021523712A5 (https=
Inventor
ウッスロー，フェリックス
ジェイ． ダイアモンド，ドン
ジェイ． ダイアモンド，ドン
コントレラス，ハイディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2021523712A publication Critical patent/JP2021523712A/ja
Publication of JPWO2019217922A5 publication Critical patent/JPWO2019217922A5/ja
Publication of JP2021523712A5 publication Critical patent/JP2021523712A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020563659A 2018-05-11 2019-05-10 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法 Pending JP2021523712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670656P 2018-05-11 2018-05-11
US62/670,656 2018-05-11
PCT/US2019/031866 WO2019217922A1 (en) 2018-05-11 2019-05-10 Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof

Publications (3)

Publication Number Publication Date
JP2021523712A true JP2021523712A (ja) 2021-09-09
JPWO2019217922A5 JPWO2019217922A5 (https=) 2022-05-18
JP2021523712A5 JP2021523712A5 (https=) 2022-05-18

Family

ID=68467105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020563659A Pending JP2021523712A (ja) 2018-05-11 2019-05-10 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法

Country Status (5)

Country Link
US (1) US12054736B2 (https=)
EP (1) EP3790578A4 (https=)
JP (1) JP2021523712A (https=)
CN (1) CN112512568A (https=)
WO (1) WO2019217922A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
EP3529353A4 (en) 2016-10-19 2020-05-13 City of Hope USE OF TRIPLEX-CMV VACCINE IN CAR-T-CELL THERAPY
KR20250005247A (ko) 2022-04-13 2025-01-09 시티 오브 호프 Cmv-hiv 특이적 키메라 항원 수용체 t 세포
WO2025184598A1 (en) * 2024-03-01 2025-09-04 City Of Hope Stable and immunogenic cmv vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316667A1 (en) * 2009-06-05 2010-12-16 Don Diamond Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835383B2 (en) 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
US7163685B2 (en) 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
US8326547B2 (en) * 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
WO2018075813A1 (en) * 2016-10-19 2018-04-26 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100316667A1 (en) * 2009-06-05 2010-12-16 Don Diamond Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, 2017, VOL.129, NO.1, PP.114-125, JPN6023016830, ISSN: 0005210859 *
VACCINE, 2010, VOL.28, PP.1547-1557, JPN6023016831, ISSN: 0005210860 *
VIROLOGY, 2010, VOL.403, PP.155-162, JPN6023016829, ISSN: 0005210861 *

Also Published As

Publication number Publication date
EP3790578A4 (en) 2022-04-06
CN112512568A (zh) 2021-03-16
WO2019217922A1 (en) 2019-11-14
US20210062221A1 (en) 2021-03-04
EP3790578A1 (en) 2021-03-17
US12054736B2 (en) 2024-08-06

Similar Documents

Publication Publication Date Title
KR102945203B1 (ko) 알파바이러스 신생항원 벡터
KR102950716B1 (ko) 신생항원의 바이러스성 전달
US20210196806A1 (en) Shared antigens
US12054736B2 (en) Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof
JP7274223B2 (ja) マイクロサテライト不安定性（ｍｓｉ）癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン
JP7486566B2 (ja) 改良ｌａｍｐ構築物
US8282935B2 (en) Materials and methods relating to improved vaccination strategies
US20220125919A1 (en) Alphavirus neoantigen vectors and interferon inhibitors
JP2022534282A (ja) 改変アデノウイルス
CN107002048A (zh) 包含外源抗原的人巨细胞病毒
JP2020536489A (ja) Ｈｐｖワクチン
KR20230006825A (ko) 전염성 질병 항원 및 백신
WO2006120474A2 (en) Compositions for inducing an immune response against tumor antigens
JPWO2020243719A5 (https=)
Wang et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector
CN100430482C (zh) 新的表达载体及其应用
Alharbi et al. Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
US20230381299A1 (en) Vaccination of hematopoietic stem cell donors with cytomegalovirus triplex composition
RU2803566C2 (ru) Неоантигенные векторы на основе альфавируса
JP2006518202A (ja) アカゲザル癌胎児性抗原、前記抗原をコードするヌクレオチド、及びその使用
KR20260057158A (ko) 알파바이러스 신생항원 벡터
KR20260052208A (ko) 신생항원의 바이러스성 전달

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205